ArticleLight, science & applications2025
A self-assembling nanoplatform for pyroptosis and ferroptosis enhanced cancer photoimmunotherapy.
Article in Light, science & applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Nanozymes for ferroptosis-based cancer theranostics.Bioactive materials · 2026Review
- Multifunctional Manganese-Based Nanocomposites for Enhanced Immunotherapy by Regulating Lactate Metabolism and Activating the cGAS-STING Pathway.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Metabolic regulation of ferroptosis in cancer: mechanisms, pharmacological inducers, and translational challenges.Apoptosis : an international journal on programmed cell death · 2026Review
- Targeting Wnt3a and Loxl2 Synergistically Induces Ferroptosis in Liver Cancer Stem Cells and Suppresses Tumorigenesis.Cancer science · 2026Article
- Organic small-molecule NIR-II fluorophores for tumor phototheranostics.Light, science & applications · 2026Review
- Nanoparticles-based phototherapy systems: molecular mechanisms and clinical applications.Signal transduction and targeted therapy · 2026Review
- Looking at the fraction with Annexin V⁺ and propidium iodide⁺: insights into cell death types from preclinical studies in solid and haematological cancers.Apoptosis : an international journal on programmed cell death · 2026Review
- Plasmonic platinum-tipped gold nanorods for tumor-targeted multimodal imaging diagnosis and NIR-II photothermal-catalytic-immuno synergetic therapy.Journal of nanobiotechnology · 2026Article
- Intelligent CpG nanoplatforms for targeted cancer immunotherapy and immune remodeling.Frontiers in pharmacology · 2026Review
- Bioengineering Strategies to Address Key Bottlenecks in Ferroptosis-Based Cancer Therapy: A Critical Review.International journal of nanomedicine · 2026Review
- Self-Trapped Excitons in Carbon Quantum Dots with Large NIR-II Photo-Thermoelectric Catalysis Induce Pyroptosis for Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ferroptosis meets cancer immunotherapy: Overcoming the crosstalk challenges through advanced drug delivery strategies.Acta pharmaceutica Sinica. B · 2025Review
- Dual-magnetically driven nanozymes for glioblastoma immunotherapy via magnetothermal and NIR-amplified ferroptosis and apoptosis.Materials today. Bio · 2025Article
- Latest developments in photosensitizers: improving stability, specificity and responsiveness.Future medicinal chemistry · 2025Review
- Photon-triggered pyroptosis and ferroptosis dual-functional nanoplatform for cancer immunotherapy.Light, science & applications · 2025Article
- Reprogramming the tumor-immune landscape via nanomaterial-induced immunogenic cell death: a mini review.Frontiers in bioengineering and biotechnology · 2025Review
- Hino-Fe Chelate Suppresses Osteosarcoma Progression through Dual Induction of Ferroptosis and NLRC4-mediated Pyroptosis: Mechanisms and Therapeutic Implications.International journal of biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The microenvironment of immunosuppression and low immunogenicity of tumor cells has led to unsatisfactory therapeutic effects of the currently developed nanoplatforms. Immunogenic cell death, such as pyroptosis and ferroptosis, can efficiently boost antitumor immunity. However, the exploration of nanoplatform for dual function inducers and combined immune activators that simultaneously trigger pyroptosis and ferroptosis remains limited. Herein, a multifunctional pH-responsive theranostic nanoplatform (M@P) is designed and constructed by self-assembly of aggregation-induced emission photosensitizer MTCN-3 and immunoadjuvant Poly(I: C), which are further encapsulated in amphiphilic polymers. This nanoplatform is found to have the characteristics of cancer cell targeting, pH response, near-infrared fluorescence imaging, and lysosome targeting. Therefore, after targeting lysosomes, M@P can cause lysosome dysfunction through the generation of reactive oxygen species and heat under light irradiation, triggering pyroptosis and ferroptosis of tumor cells, achieving immunogenic cell death, and further enhancing immunotherapy through the combined effect with the immunoadjuvant Poly(I: C). The anti-tumor immunotherapy effect of M@P has been further demonstrated in in vivo antitumor experiment of 4T1 tumor-bearing mouse model with poor immunogenicity. This research would provide an impetus as well as a novel strategy for dual function inducers and combined immune activators enhanced photoimmunotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.